SARS-CoV-2 nsp14-IN-6
SARS-CoV-2 nsp14-IN-6 (Compound 35) is a SARS-CoV-2 Nsp14 MTase inhibitor with an IC50 of 0.24 μM. SARS-CoV-2 nsp14-IN-6 has potent antiviral activity against SARS-CoV-2 replication. SARS-CoV-2 nsp14-IN-6 increases lipophilicity, further improving cell permeability. SARS-CoV-2 nsp14-IN-6 can be used for human coronaviruses research[1].
Product Specifications
UNSPSC
12352005
Target
SARS-CoV
Related Pathways
Anti-infection
Field of Research
Infection
Smiles
O=C(O)C1=CC=C(C2=NN(C3=CC=C(C#N)C(Cl)=C3)C(CC)C2)C(C)=C1
Molecular Formula
C20H18ClN3O2
Molecular Weight
367.83
References & Citations
[1]Smyth EB, et al. Design and Synthesis of Pyrazoline Inhibitors of SARS-CoV‑2 NSP14. ACS Med Chem Lett. 2025 Sep 5;16 (10) :1918-1926.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC040676-100 1x 100 µL
MUC18 / Mucin 18 / CD146 (OJ79c), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC740178-100 1x 100 µL
CD50 (ICAM-3) (186-2G9), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC680181-500 1x 500 µL
CD59 (heavy chain of Protectin) (BRA-10G), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC471820-100 1x 100 µL
Ep-CAM / CD326 (Epithelial Marker) (rVU-1D9), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details